GENENTECH TO PRESENT NEW DATA AT AAN SHOWING SUPERIOR EFFICACY OF NVESTIGATIONAL MEDICINE OCRELIZUMAB VERSUS COMPARATORS ON DISEASE [...]
Iva Fattorini, MD, has stepped down from her role as Global Chair of the Arts & Medicine Institute, effective Jan. 1. Cleveland Clinic [...]
DERBY — Joseph Guarnaccia, M.D., clinical director of the Multiple Sclerosis Treatment Center at Griffin Hospital, was recently inducted [...]
A Phase III trial of MedDay's multiple sclerosis drug has missed its primary endpoint. The drug, which made headlines in April when it [...]
Wednesday, October 21, 2015 7:31 am EDT CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Phase 3 ASCEND study investigating natalizumab in the [...]
Rockland, Massachusetts, October 12, 2015 – EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today [...]
Thursday, October 8, 2015 1:00 am EDT CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, aSanofi company, today announced positive new [...]
Genentech’s Ocrelizumab First Investigational Medicine to Show Positive Pivotal Study Results in Both Relapsing and Primary Progressive [...]
EMD Serono Announces Recipients of the Third Annual €1 Million Grant for Multiple Sclerosis Innovation Four research grants awarded [...]
New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis Additional MRI data on [...]